KYMRIAH^®

Indications

Kymriah^® is a genetically-modified autologous immunocellular therapy indicated for the treatment of:

• Paediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.
• Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
• Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

Novartis Risk Management Plan (RMP) Educational Materials for Patients

Novartis Risk Management Plan (RMP) Educational Materials for Healthcare Professionals